Utilizing State-of-the-Art DEL Technology to Discover Compounds that Hit Challenging Therapeutic Targets

Life Sciences, Pharmaceutical, Drug Discovery & Development, Laboratory Technology,
  • Thursday, December 01, 2022

DNA-encoded small molecule libraries (DELs) created using combinatorial chemistry and synthetic oligonucleotides are being successfully applied to drug discovery projects across the pharmaceutical industry. There have been many recent advances in DEL technology with the promise of helping to deliver ever more efficacious and beneficial small molecule-based tools and therapies.

In this webinar, the featured speaker will review the use of state-of-the-art DEL technology to uncover compounds that modulate challenging therapeutic targets, including the following applications:

  • Identification of hits to target in complex biological systems
  • Targeted protein degradation
  • Discovery of irreversible covalent binders
  • Identifying binders to nucleic acid targets and
  • Enhanced hit identification of DEL screen output using machine learning

Register for this webinar to learn about leading advances in DEL technology.


John (JP) Guilinger, X-Chem

John (JP) Guilinger, PhD, Director, Lead Discovery and Biochemistry, X-Chem

JP is a leading innovator in the DNA-encoded library (DEL) field. As a part of X-Chem’s scientific team, JP has helped develop X-Chem into a world-leading drug discovery engine with first-rate DEL capabilities serving the biopharma industry. JP has been an integral project team member, contributing to the execution of >100 DEL projects with collaborators. Under JP’s scientific leadership, X-Chem has developed and operationalized advances in DEL screens for covalent irreversible inhibitor and screening targets in cellular lysate, among other advancements. Before joining X-Chem, JP was a graduate student at Harvard University in David Liu’s group, where he led development and studies of genome editing technologies, including CRISPR-Cas9. JP is a thought leader in the DEL space, with key DEL publications to his name. He received his BS in biochemistry from Brandeis University and holds a PhD in molecular and cellular biology from Harvard University.

Message Presenter

Who Should Attend?

  • Current DEL practitioners
  • Teams with challenging targets interested in hit identification using DEL screens

What You Will Learn

Attendees will understand the state-of-the-art and recent advances in DEL technologies

Xtalks Partner


X-Chem is a leader in small molecule drug discovery services for pharmaceutical and biotech companies. As pioneers of DNA-encoded chemical library (DEL) technology, the company leverages its market-leading DEL platform to discover novel small molecule leads against challenging, high-value therapeutic targets. As experts in medicinal chemistry, X-Chem can take those leads and progress them to clinical candidates with unmatched speed. Throughout the process, X-Chem’s advanced proprietary artificial intelligence (AI) technology accelerates all steps in the process. X-Chem also provides libraries, reagents and informatic tools to allow DEL operators to get the most of their DEL platform. X-Chem empowers its partners to effectively build drug pipelines from target to clinical candidate, enhanced with AI. For further information, please visit www.x-chemrx.com.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account